In the era with growing scientific focus on extending human life, an increasing number of researchers, engineers, and innovators are examining the biological boundaries of aging. At the forefront of this effort is 600and1, a biotechnology incubator and venture capital fund focused on addressing one of humanity’s most fundamental challenges: mortality. Through multidisciplinary research and strategic investment, the organization seeks to redefine current understandings of aging and longevity.
Leadership by a Longevity Triple Doctor
Dr. Berenika Maciejewicz serves as Chief Scientific Advisor to the venture. Her extensive and multidisciplinary academic background positions her among the most versatile thinkers in contemporary science. She holds a PhD in Biomedical Engineering from the Einstein Medical Institute, a PhD in Neuroscience from London Metropolitan University, and a medical degree, making her a rare triple doctor. Additionally, she has earned a Certificate of Achievement from Stanford Medicine’s Genetics and Genomics program, completed advanced oncology-immunology programs at Harvard Medical School, and undertook the Advances in Stem Cell Biology training at the prestigious Institute Pasteur in Paris.
Advancing Human Longevity via Mitochondrial Research
At the core of 600and1’s strategy is a bold scientific objective: bioengineering extended lifespan and healthspan through targeted cellular interventions. The company focuses on mitochondria, the organelles responsible for cellular energy production, which are increasingly recognized as pivotal regulators of aging processes.
AI Research-Driven Approach to Aging and Disease
Dr. Maciejewicz’s research underscores the critical role of mitochondrial function and integrity in aging and the onset of age-related diseases. By prioritizing interventions that enhance mitochondrial activity—particularly ATP production—600and1 aims to develop therapies that not only extend lifespan but also improve physiological resilience and functional health across extended years.
A Vision for Long-Term Human Survival
The company’s name and mission draw symbolic inspiration from the biblical figure Noah, believed to have lived for 600 years. In this spirit, 600and1 envisions itself as a modern “ark”: a venture platform and innovation hub designed to preserve and extend human life through scientific advancement. Its approach emphasizes the integration of advanced biotechnology with artificial intelligence to address the complex biological mechanisms driving aging and cellular degeneration.
This framework functions both as a metaphor and as a guiding principle for the company’s research and investment strategy. By combining AI-driven analytical tools with next-generation bioengineering, 600and1 aims to push the frontiers of longevity science, working toward a future in which aging is better understood, modulated, and partially reversible.
Expanding the Frontiers of Longevity Research
Beyond its internal initiatives, 600and1 is dedicated to supporting the broader scientific community engaged in longevity and healthspan research. Through its venture fund and research programs, the organization provides financial and strategic support to pioneering researchers and innovators. In doing so, 600and1 continues to advance its mission of addressing what it identifies as humanity’s most enduring challenge: death.